XNK Therapeutics strengthens its scientific network with two more advisors

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala University, and Dr. Rizwan Romee, Associate Professor of Medicine at Harvard Medical School, as scientific advisors. Together with the other advisors, they will play a key role in the future development of XNK’s proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.

XNK Therapeutics adds three scientific advisors to bolster platform technology

XNK Therapeutics AB (“XNK”) today announced the strengthening of the company’s expertise by the appointment of Ola Landgren, M.D., Ph.D., Fredrik Schjesvold M.D., Ph.D. and Johan Lund M.D., Ph.D. These scientific advisors are key to the company’s plan to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.

XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy

September 29, 2021

XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022.

XNK Therapeutics receives US orphan drug status

XNK Therapeutics AB (“XNK”) today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the…

First results from the ACP-001 study presented at EHA

Today results from the first-in-human study ACP-001 was made public at the 2020 EHA meeting. Key findings from the study: Overall survival (OS) 100% after a median follow-up time of 60 months…

XNK Therapeutics appoints Hans Ericson as CFO

XNK Therapeutics AB (“XNK”) today announced the appointment of Hans Ericson as Chief Financial Officer Hans Ericson is a senior finance professional with more than 20 years’ experience in…

XNK Therapeutics appoints Johan Liwing as CEO

XNK Therapeutics AB (“XNK”) today announced its appointment of Johan Liwing as CEO of the company and prepares for the next phase of development of its technology platform and leading drug…

XNK Therapeutics granted SEK1m by Sweden’s Vinnova

XNK Therapeutics AB (“XNK”) today announced that Vinnova, a Swedish government-sponsored innovation agency, has granted XNK SEK1 million to upscale production of CellProtect. “We are extremely…

Agneta Edberg appointed to board of XNK Therapeutics

XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors. Agneta Edberg has over 25 years’ experience from leading…